These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22412237)

  • 1. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.
    Tempelhof MW; Benzuly KH; Fintel D; Krichavsky MZ
    Tex Heart Inst J; 2012; 39(1):86-91. PubMed ID: 22412237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
    Yang EH; Perez E; Zhiroff KA; Burstein S
    Tex Heart Inst J; 2011; 38(2):174-8. PubMed ID: 21494531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eptifibatide-induced thrombocytopenia.
    Refaat M; Smith AJ; Edmundowicz D
    J Thromb Thrombolysis; 2008 Apr; 25(2):204-6. PubMed ID: 18008040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible thrombocytopenia associated with eptifibatide.
    Yoder M; Edwards RF
    Ann Pharmacother; 2002 Apr; 36(4):628-30. PubMed ID: 11918511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eptifibatide-induced thrombocytopenia and thrombosis.
    Epelman S; Nair D; Downey R; Militello M; Askari AT
    J Thromb Thrombolysis; 2006 Oct; 22(2):151-4. PubMed ID: 17008982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe thrombocytopenia possibly related to readministration of eptifibatide.
    Paradiso-Hardy FL; Madan M; Radhakrishnan S; Hurden S; Cohen EA
    Catheter Cardiovasc Interv; 2001 Sep; 54(1):63-7. PubMed ID: 11553950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.
    Russell KN; Schnabel JG; Rochetto RP; Tanner MC
    Pharmacotherapy; 2009 Jul; 29(7):867-74. PubMed ID: 19558261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eptifibatide-induced acute profound thrombocytopenia: a case report.
    Graidis C; Golias C; Dimitriadis D; Dimitriadis G; Bitsis T; Dimitrelos I; Tsiakou A; Charalabopoulos K
    BMC Res Notes; 2014 Feb; 7():107. PubMed ID: 24564943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario.
    Bhatia N; Sawyer RD; Ikram S
    Methodist Debakey Cardiovasc J; 2017; 13(4):248-252. PubMed ID: 29744018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
    Dursunoglu D; Taskoylu O; Gür S; Sari I
    Asian Cardiovasc Thorac Ann; 2013 Feb; 21(1):74-6. PubMed ID: 23430426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute thrombocytopenia associated with eptifibatide therapy.
    Khaykin Y; Paradiso-Hardy FL; Madan M
    Can J Cardiol; 2003 Jun; 19(7):797-801. PubMed ID: 12813613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed profound thrombocytopenia associated with eptifibatide.
    Onitilo AA
    Am J Hematol; 2006 Dec; 81(12):984. PubMed ID: 16804935
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.
    Ben Morrison T; Horst BM; Brown MJ; Bell MR; Daniels PR
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):575-82. PubMed ID: 22448399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute profound thrombocytopenia associated with eptifibatide therapy.
    Nagge J; Jackevicius C; Dzavik V; Ross JR; Seidelin P
    Pharmacotherapy; 2003 Mar; 23(3):374-9. PubMed ID: 12627937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting.
    Salengro E; Mulvihill NT; Farah B
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):73-5. PubMed ID: 12508201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eptifibatide-induced thrombocytopenia leading to acute stent thrombosis.
    Dézsi DA; Bokori G; Faluközy J; Bujáky C; Fogarassy G; Veress G; Aradi D
    J Thromb Thrombolysis; 2016 Apr; 41(3):522-4. PubMed ID: 26305043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.
    Greinacher A; Fuerll B; Zinke H; Müllejans B; Krüger W; Michetti N; Motz W; Schwertz H
    Blood; 2009 Aug; 114(6):1250-3. PubMed ID: 19429867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
    Sharma A; Ferguson C; Bainey KR
    Can J Cardiol; 2015 Jun; 31(6):809-11. PubMed ID: 25913474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.